Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
28 April 2020 - 6:03AM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the company will report 2020 first quarter financial results on
Thursday, May 7, 2020, after market close. Subsequently, Adamas’
management team will host a conference call and webcast at 5:00
p.m. Eastern Time to discuss the financial results and provide a
corporate update.
Investor Conference Call and
WebcastThe conference call can be accessed by dialing
(844) 215-3280 for participants in the U.S. or Canada and (484)
747-6383 for international callers. All callers must provide the
following Conference ID: 3483897. The webcast can be accessed live
via the investor section of the Adamas website at
ir.adamaspharma.com/events-presentations and will be available for
replay until August 7, 2020.
About Adamas Pharmaceuticals,
Inc.At Adamas, our purpose and vision are clear: deliver
innovative medicines that make a clinically meaningful difference
for patients, caregivers and society. We are a fully-integrated
company focused on growing a portfolio of therapies to address a
range of neurological diseases. In 2018, Adamas successfully
launched GOCOVRI® (amantadine) extended-release capsules, the first
and only FDA-approved medicine for the treatment of dyskinesia in
patients with Parkinson’s disease receiving levodopa-based therapy,
with or without concomitant dopaminergic medications. GOCOVRI is
also the only medicine clinically proven to reduce both dyskinesia
and OFF. For more information, please visit
www.adamaspharma.com.
Contact
Investors: Peter VozzoManaging Director,
Westwicke443-213-0505 peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Corporate
Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2024 to May 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Adamas Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles